New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease -October 25, 2023 at 10:52 am EDT

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function.First study of a tau targeting drug that shows reduction of aggregated tau...

Related Keywords

United States ,Boston ,Massachusetts ,Cambridge ,Cambridgeshire ,United Kingdom ,America ,Jack Cox ,Priya Singhal ,Chuck Triano ,Asia Pacific ,Brightfocus Foundation ,Youtube ,Linkedin ,Head Of Development At Biogen ,Alzheimer Association ,Exchange Commission ,Facebook ,Nasdaq ,Biogen Inc ,International Conference On Alzheimer ,Clinical Dementia Rating Sum ,Mini Mental State Exam ,Functional Activities Questionnaire ,International Conference ,North America ,Safe Harbor ,Tau Protein ,Accessed September ,From Discovery ,Tau Topic ,Accessed October ,Markets ,